Related Experiment Video
Updated: Feb 6, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
Published on: March 17, 2020
A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
Lixia Ju1, Mingquan Han2, Jinmei Su2
1Department of Integrative Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No. 507 Zheng Min Road, Shanghai, 200433, People's Republic of China. jvlixia@126.com.
Abstract:
It is widely known that ROS1 rearrangement mostly occurs in the adenocarcinoma subtype of non-small-cell lung cancer. Patients with squamous cell carcinoma harboring ROS1 rearrangement are extremely rare. This is a case report of a squamous cell carcinoma patient with ROS1 rearrangement. An 84-year-old Chinese woman with a about 6.6 cm mass in the right middle lobe and right pleural effusion, enlarged mediastinal and hilar lymph nodes was diagnosed with stage IIIB lung squamous cell carcinoma harboring ROS1 rearrangement is highly sensitive to crizotinib in the first treatment setting. This is the first time to report lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib. We hope that oncologists will notice this phenomenon and it will help the lung squamous cell carcinoma patient to get longer overall survival time.
Insights
This case report details an extremely rare instance of lung squamous cell carcinoma with ROS1 rearrangement. The patient showed high sensitivity to crizotinib, offering new treatment possibilities for this rare cancer subtype.
Area of Science:
- Oncology
- Genetics
- Pulmonology
Background:
- ROS1 rearrangements are predominantly found in non-small cell lung cancer (NSCLC) adenocarcinoma.
- ROS1 rearrangements are exceptionally rare in NSCLC squamous cell carcinoma.
- Identifying actionable mutations in rare cancer subtypes is crucial for effective treatment.
Observation:
- An 84-year-old Chinese woman was diagnosed with stage IIIB lung squamous cell carcinoma.
- The patient presented with a large right middle lobe mass, pleural effusion, and enlarged mediastinal and hilar lymph nodes.
- Genetic analysis revealed a ROS1 rearrangement in the tumor tissue.
Findings:
- The patient's squamous cell carcinoma demonstrated high sensitivity to crizotinib, a targeted therapy typically used for ROS1-positive lung cancers.
- This represents the first reported case of lung squamous cell carcinoma with a ROS1 rearrangement that is sensitive to crizotinib treatment.
Implications:
- This finding challenges the current understanding of ROS1 rearrangements being exclusive to adenocarcinoma.
- Highlights the potential benefit of ROS1 testing in non-small-cell lung cancer patients, including squamous cell carcinoma.
- Suggests that crizotinib may be a viable first-line treatment option for select lung squamous cell carcinoma patients with ROS1 rearrangements, potentially improving overall survival.
Related Concept Videos
[3,3] Sigmatropic Rearrangement of 1,5-Dienes: Cope Rearrangement
[3,3] Sigmatropic Rearrangement of Allyl Vinyl Ethers: Claisen Rearrangement
Preparation of Diols and Pinacol Rearrangement
The reaction begins with transferring a proton from the acid catalyst to one of the hydroxyl groups, producing an oxonium ion.
Lung Capacity
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Mechanism
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview

